Bio-Responsive Au-miR-183 Inhibitor Enhances Immunotherapy in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death

Scientists constructed a bio-responsive Au-miR-183 inhibitor delivery system targeting liver cancer stem cells, and adopted the strategy of combining αPD-L1 immunotherapy.